Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
46
ACAD Quote, Financials, Valuation and Earnings
Last price:
$24.00
Seasonality move
:
9.35%
Day range:
$23.58 - $24.22
52-week range:
$13.40 - $28.35
Dividend yield:
0%
P/E ratio:
15.44x
P/S ratio:
3.86x
P/B ratio:
4.42x
Volume:
2.2M
Avg. volume:
1.3M
1-year change:
18.24%
Market cap:
$4.1B
Revenue:
$957.8M
EPS (TTM):
$1.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
AXSM
Axsome Therapeutics, Inc.
|
$193.3M | -$0.73 | 58.1% | -49.24% | $216.09 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$56.2M | -$0.78 | 76.93% | -4.47% | $141.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.99 | $31.21 | $4.1B | 15.44x | $0.00 | 0% | 3.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
AXSM
Axsome Therapeutics, Inc.
|
$183.72 | $216.09 | $9.3B | -- | $0.00 | 0% | 16.11x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.45 | $7.87 | $24.2M | -- | $0.00 | 0% | 3.93x |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$99.78 | $141.80 | $6.7B | -- | $0.00 | 0% | 36.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
AXSM
Axsome Therapeutics, Inc.
|
74.78% | -0.322 | 3.58% | 1.45x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.330 | -- | 5.66x |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
63.6% | 0.387 | 3.86% | 4.31x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
AXSM
Axsome Therapeutics, Inc.
|
$156.7M | -$32.9M | -82.07% | -327.97% | -19.26% | $988K |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$45.7M | -$52.7M | -65.1% | -509.34% | -102.64% | -$66.6M |
ACADIA Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ACAD or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 16.99%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About ACAD or ALNY?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.21, signalling upside risk potential of 30.1%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is ACAD or ALNY More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.660, which suggesting that the stock is 33.951% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock ACAD or ALNY?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or ALNY?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.44x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.86x versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns ACAD or AXSM?
Axsome Therapeutics, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -27.62%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M -
What do Analysts Say About ACAD or AXSM?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.21, signalling upside risk potential of 30.1%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $216.09 which suggests that it could grow by 17.62%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 AXSMAxsome Therapeutics, Inc.16 1 0 -
Is ACAD or AXSM More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.660, which suggesting that the stock is 33.951% less volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.011%.
-
Which is a Better Dividend Stock ACAD or AXSM?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or AXSM?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Axsome Therapeutics, Inc. quarterly revenues of $171M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.44x while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.86x versus 16.11x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M AXSMAxsome Therapeutics, Inc.16.11x -- $171M -$47.2M
-
Which has Higher Returns ACAD or MRKR?
Marker Therapeutics, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -162.11%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About ACAD or MRKR?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.21, signalling upside risk potential of 30.1%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 442.53%. Given that Marker Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 MRKRMarker Therapeutics, Inc.3 0 0 -
Is ACAD or MRKR More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.660, which suggesting that the stock is 33.951% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.218%.
-
Which is a Better Dividend Stock ACAD or MRKR?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or MRKR?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.44x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.86x versus 3.93x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M MRKRMarker Therapeutics, Inc.3.93x -- $1.2M -$2M
-
Which has Higher Returns ACAD or RYTM?
Rhythm Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -103.13%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M RYTMRhythm Pharmaceuticals, Inc.89.08% -$0.82 $408.8M -
What do Analysts Say About ACAD or RYTM?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.21, signalling upside risk potential of 30.1%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $141.80 which suggests that it could grow by 42.11%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 RYTMRhythm Pharmaceuticals, Inc.11 1 0 -
Is ACAD or RYTM More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.660, which suggesting that the stock is 33.951% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.005, suggesting its more volatile than the S&P 500 by 100.46%.
-
Which is a Better Dividend Stock ACAD or RYTM?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or RYTM?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Rhythm Pharmaceuticals, Inc. quarterly revenues of $51.3M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.44x while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.86x versus 36.43x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M RYTMRhythm Pharmaceuticals, Inc.36.43x -- $51.3M -$52.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
